Literature DB >> 15316409

Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening.

F Gleeson1, E Ryan, S Barrett, J Crowe.   

Abstract

BACKGROUND: In Ireland, the homozygote frequency of the C282Y mutation in the HFE gene is 1/83. The biochemical expression of this mutation is high in haemochromatosis (HH) individuals identified through family screening, but the clinical expression of the mutation in Irish HH subjects to date has not been investigated fully.
OBJECTIVES: To determine the clinical, biochemical and histological penetrance of the C282Y mutation in Irish C282Y homozygotes identified through family screening.
METHOD: Two hundred and nine C282Y homozygous individuals comprising of 172 first-degree relatives, 31 second-degree relatives and four unrelated individuals were identified following HFE mutation analysis of 167 families. The following variables were analysed: age at identification, gender, fasting transferrin saturation, fasting serum ferritin, liver enzymes, clinical symptomatology, liver histopathology and histochemical iron staining.
RESULTS: An elevated transferrin saturation in combination with an elevated ferritin was present in 43.4% of males and 23.3% of females. Abnormal liver enzymes were found in 32.3% of males. Diabetes, a haemochromatosis-specific association, was noted in 2.8% of males. Of those individuals requiring liver histopathology evaluation, 38% had moderate-to-severe iron staining, and 42% had fibrosis; 2.8% of the biopsied cohort had cirrhosis. Thus, HH cirrhotics were identified in less than 1% of the screened population.
CONCLUSION: Although the homozygote frequency in Ireland is very high, the prevalence of advanced liver disease was less than 1% of the family members screened. Nevertheless, 42% of biopsied patients had histological evidence of iron overload-related architectural change and 2.8% had cirrhosis. This cohort of young people had previously unrecognized biochemical iron overload and histopathological change. This emphasizes the importance and value of both genetic and biochemical screening in first-degree relatives of identified homozygotes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316409     DOI: 10.1097/00042737-200409000-00008

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Perceptions and attitudes about HFE genotyping among college-age adults.

Authors:  Bret L Hicken; Aimee Foshee; Diane C Tucker
Journal:  J Genet Couns       Date:  2005-12       Impact factor: 2.537

Review 2.  [Hemochromatosis].

Authors:  B Oppl; J Zwerina
Journal:  Z Rheumatol       Date:  2015-09       Impact factor: 1.372

Review 3.  HFE-related hemochromatosis: an update for the rheumatologist.

Authors:  Emma Husar-Memmer; Andreas Stadlmayr; Christian Datz; Jochen Zwerina
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

4.  HFE genotyping in patients with elevated serum iron indices and liver diseases.

Authors:  Andreia Silva Evangelista; Maria Cristina Nakhle; Thiago Ferreira de Araújo; Clarice Pires Abrantes-Lemos; Marta Mitiko Deguti; Flair José Carrilho; Eduardo Luiz Rachid Cançado
Journal:  Biomed Res Int       Date:  2015-01-14       Impact factor: 3.411

5.  Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance.

Authors:  Michael A Schmidt; Thomas J Goodwin
Journal:  Metabolomics       Date:  2013-06-27       Impact factor: 4.290

6.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.